Abstract:Abstract Background. Immune checkpoint molecules are essential for modulating immune responses and maintaining self-tolerance. While immune checkpoint inhibitors have improved the treatment of a broad spectrum of cancers, many of them are also believed to play a critical role in the induction of immune related adverse events (irAEs) such as autoimmune and inflammatory diseases. For example, patients receiving anti-PD-1 based therapy frequently develop colitis. In addition, dysfunctional PD-1 signalling has also been linked to increasing susceptibility to autoimmune and inflammatory diseases. Therefore, immune checkpoint molecule agonist which could, like their natural ligands, confer a great potential in suppressing excessively activated immune response observed in autoimmune and inflammatory diseases. Methods. In the first part, the proinflammation effects of a Pembrolizumab analogue was evaluated in a MC38-OVA colorectal tumor bearing mice treated with or without DSS. In the second part, an anti-hPD-1 agonistic antibody at 10 mg/kg was evaluated in acute DSS IBD model. Results. In the MC38-OVA colorectal cancer model, mice treated with Pembrolizumab analogue only or Pembrolizumab analogue plus 1.5% DSS showed significant tumor growth inhibition (100% TGI and 92.01% TGI, respectively at Day 27) compared to their respective control group, which suggests this Pembrolizumab analogue induced robust anti-tumor immunity against MC38-OVA tumors. Notably, 8/8 mice treated with Pembrolizumab analogue only showed complete tumor regression, while only 5/8 mice treated with Pembrolizumab analogue plus DSS showed complete tumor regression. Taken together, these results suggest DSS treatment leading to a proinflammatory context could compromise anti-hPD-1 anti-tumor efficacy. Moreover, mice treated with Pembrolizumab analogue plus DSS also showed 3.59% more Body Weight Loss (BWL) in comparison to 1.5% DSS only group, suggesting that Pembrolizumab analogue could exacerbate DSS induced colitis. In the acute DSS IBD model, mice treated with an agonistic anti-hPD-1 antibody showed significantly lower disease score (DAI 5.3 vs DAI 2.4) and less BWL (BWL 13.44% vs BWL 3.31%) in comparison to isotype control group. In addition, pathology results showed that mice treated with agonistic anti-hPD-1 exhibits significantly less inflammatory cell infiltration and colonic lesions when compared to isotype control group. Conclusion. In summary, we reported in this study that blocking of PD-L1/PD-1 signalling axis by a PD-1 antagonist activated T cell function which at the same time aggravated DSS induced colitis in mouse. In contrast, activation of PD-L1/PD-1 signalling pathway by a PD-1 agonist alleviated DSS induced colitis. Citation Format: Tao Yang, Rongfei Lu, kaixia lian, Likun Zhang, Dawei Wang, Xinhe Feng, Xiaoyu An, Jessie (Jingjing) Wang, Carl K. Edwards. PD-1/PD-L1 signalling axis, “a double-edged sword” in DSS induced colitis mouse model. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5134.

Inhibition of PD-1 Protects Against TNBS-Induced Colitis Via Alteration of Enteric Microbiota

Blockage of Tumor Necrosis Factor Prevents Intestinal Mucosal Inflammation Through Down-Regulation of Interleukin-23 Secretion

PD-1 signaling facilitates activation of lymphoid tissue inducer cells by restraining fatty acid oxidation

Prevention of Experimental Colitis in SCID Mice Reconstituted with CD45RBhigh CD4+ T Cells by Blocking the CD40-CD154 Interactions1

Gut microbiota modulation and anti-inflammatory properties of mixed lactobacilli in dextran sodium sulfate-induced colitis in mice

Inhibitory effect of Bifidobacterium bifidum ATCC 29521 on colitis and its mechanism

Relationship between anti-tumor necrosis factor -α monoclonal antibody and chronic colitis in mice.

Isosteviol Attenuates DSS-induced Colitis by Maintaining Intestinal Barrier Function Through PDK1/AKT/NF-κB Signaling Pathway

Impact of Bifidobacterium Longum NSP001 on DSS-induced Colitis in Conventional and Humanised Mice

Lactobacillus Johnsonii Glj001 Prevents Dss-Induced Colitis in Mice by Inhibiting M1 Macrophage Polarization Via Gut Microbiota-Scfas Axis

Prevotellaceae produces butyrate to alleviate PD-1/PD-L1 inhibitor-related cardiotoxicity via PPARα-CYP4X1 axis in colonic macrophages

Amending microbiota by targeting intestinal inflammation with TNF blockade attenuates development of colorectal cancer

Resveratrol modulates the gut microbiota to prevent murine colitis development through induction of Tregs and suppression of Th17 cells

Targeted delivery of Fc-fused PD-L1 for effective management of acute and chronic colitis

Targeting Purinergic Receptor P2RX1 Modulates Intestinal Microbiota and Alleviates Inflammation in Colitis

Inhibition of NLRP3 Attenuates Sodium Dextran Sulfate-Induced Inflammatory Bowel Disease Through Gut Microbiota Regulation.

Mitigation of Dextran-Sodium-Sulfate-Induced Colitis in Mice through Oral Administration of Microbiome-Derived Inosine and Its Underlying Mechanisms

Weissella paramesenteroides NRIC1542 inhibits dextran sodium sulfate-induced colitis in mice through regulating gut microbiota and SIRT1/NF-κB signaling pathway

Effect of Bifidobacterium on Expression of Inflammatory Cytokine in Experimental Colitis Rats

Abstract 5134: PD-1/PD-L1 Signalling Axis, “a Double-Edged Sword” in DSS Induced Colitis Mouse Model

Berberine attenuates TNBS-induced colitis in mice by improving the intestinal microbiota